- Home
- Companies
- Sumitomo Pharma Oncology, Inc.
- Products
- Sumitomo - Model DSP-0509 - TLR7 ...
Sumitomo -Â Model DSP-0509 - TLR7 Agonist
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor activity.14
Understanding the target
TLRs play a vital role in innate immunity by inducing the production of multiple cytokines and activating immune cells.18 Activation of TLRs may increase immune responses to tumors.18
Clinical evidence
Clinical studies have indicated that TLRs, including TLR7, may be eligible therapeutic targets in a variety of cancers.19
Preclinical evidence
In preclinical models, DSP-0509 was shown to promote cytokine induction and cytotoxic T-lymphocyte activation mediated by an agonistic effect on TLR7 expressed in plasmacytoid dendritic cells.17
Clinical development
DSP-0509 is currently being evaluated in a phase I clinical trial in solid tumors.
